(MENAFN- America News Hour)
Research Nester published a report titled “Carvedilol Drug Market : Global Demand Analysis & Opportunity Outlook 2031” which delivers detailed overview of the global carvedilol drug market in terms of market segmentation by product, application, distribution channel, and by region.
Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.
The global carvedilol drug market is anticipated to attain a significant CAGR over the forecast period, i.e., 2022 – 2031. The market is segmented on the basis of application into high blood pressure, congestive heart failure (CHF), ventricular dysfunction, and others, out of which, the congestive heart failure (CHF) segment is anticipated to hold a substantial share over the forecast period. This can be accounted to the increasing prevalence of congestive heart failure, backed by the poor lifestyle and high levels of cholesterol among the population globally.
Download Sample PDF of this Report @
The global carvedilol drug market is estimated to grow on the back of increasing cases of heart failure, as carvedilol is given to clinically stable patients during a stroke or heart attack. Moreover, the growing prevalence of hypertension and cardiovascular diseases is estimated to boost the market growth. According to the data by the World Health Organization (WHO), cardiovascular diseases were the cause of 17.9 million deaths in 2019. Along with this, over 1.28 billion adults aged 30-79 years are diagnosed with hypertension worldwide annually.
On the basis of geographical analysis, the global carvedilol drug market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in the North America region is anticipated to gain the largest market share throughout the forecast period owing to the high prevalence of heart failure and high blood pressure in the region. According to the data by the Center for Disease Control and Prevention (CDC), heart failure was the cause for 379,800 deaths in 2018.
The research is global in nature and covers detailed analysis on the market in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa). In addition, analysis comprising market size, Y-O-Y growth & opportunity analysis, market players' competitive study, investment opportunities, demand for future outlook etc. has also been covered and displayed in the research report.
Growing Incidences of Heart Failure to boost the Market Growth
Carvedilol is a non-selective adrenergic blocking drug, which is used only to treat heart failure or myocardial infarction. It is not a prescription medication for cardiovascular diseases. As a result, the increasing prevalence of heart failure amongst patients is estimated to boost the market growth. Cardiovascular diseases (CVDs) and hypertension are some major causes of heart failure, therefore, the growing prevalence of these diseases is also expected to boost the market growth.
However, carvedilol drug has some side effects, such as, dizziness, and tiredness, and is unsafe for consumption during pregnancy, which are expected to operate as key restraint to the growth of global carvedilol drug market over the forecast period.
Download Sample PDF of this Report @
This report also provides the existing competitive scenario of some of the key players of the global carvedilol drug market which includes company profiling of Sun Pharmaceutical Industries Limited, Novartis AG, Sanofi-aventis Groupe, Abbott Laboratories, Merck & Co., Inc., Siemens Healthcare GmbH, Amgen Inc., Boehringer Ingelheim International GmbH, Daiichi Sankyo Company, Limited, and Pfizer Inc. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global carvedilol drug market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.
Research Nester is a one-stop service provider, leading in strategic market research and consulting with an unbiased and unparalleled approach towards helping global industrial players, conglomerates and executives to make wise decisions for their future investment and expansion by providing them qualitative market insights and strategies while avoiding future uncertainties. We believe in honesty and sheer hard work that we trust is reflected in our work ethics. Our vision is not just limited to gain the trust of our clients but also to be equally respected by our employees and being appreciated by the competitors.
MENAFN31072022004545010068ID1104621675
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.